Stock Price Quote

TTK HEALTHCARE LTD.

NSE : TTKHLTCAREBSE : 507747ISIN CODE : INE910C01018Industry : Pharmaceuticals & DrugsHouse : TTK
BSE1222.0021.1 (+1.76 %)
PREV CLOSE ( ) 1200.90
OPEN PRICE ( ) 1205.00
BID PRICE (QTY) 1191.05 (2)
OFFER PRICE (QTY) 1221.90 (56)
VOLUME 1127
TODAY'S LOW / HIGH ( )1121.30 1228.00
52 WK LOW / HIGH ( )991 1923
NSE1200.009.3 (+0.78 %)
PREV CLOSE( ) 1190.70
OPEN PRICE ( ) 1182.50
BID PRICE (QTY) 1200.00 (28)
OFFER PRICE (QTY) 1202.95 (9)
VOLUME 4498
TODAY'S LOW / HIGH( ) 1182.50 1228.95
52 WK LOW / HIGH ( )1101.05 1893.95
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1958
Management Info
T T Raghunathan - Chairman - Managing Director
Registered Office

Address No 6 , Cathedral Road, , ,
Chennai,
Tamil Nadu-600086

Phone 044-28116106-08

Email info@ttkhealthcare.com

Website www.ttkhealthcare.com

Registrars Details
Data Software Research Co Pvt Ltd
19 Pycroft Garden Road,Off Haddows Road,Nungambakkam,Chennai
Listing : BSE, NSE

NEWS

04Apr TTK Healthcare informs about complianc
TTK Healthcare has informed that it enclosed a copy of the Certificate d..
16Jul Ttk Healthcare informs about loss of s
Ttk Healthcare has informed that Ketan Narendra Desai (Claimant), the le..
22Dec Ttk Healthcare informs about clarifica
With acknowledge receipt of communication L/SURV/ONL/PV/NP/2023-2024/497..
21Nov Ttk Healthcare informs about loss of s
Ttk Healthcare has informed that it enclosed Certificate under Reg 39(3)..
03Nov Ttk Healthcare submits unaudited finan
Ttk Healthcare has informed that it enclosed the Unaudited Financial Res..

Financials

in Millions
QTR Dec 24 ANNUAL 24
Net Profit167.34628.41
Gross Profit 225.95 841.19
Operating Profit 255.29999.34
Net Sales 2047.457527.94

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  29264.55 (1.16%)
M.Cap ( in Cr)61941.72
Neuland Laboratories (BSE)
peergroup  11275.85 (2.98%)
M.Cap ( in Cr)14355.36
Glaxosmithkline Phar (BSE)
peergroup  2720.50 (5.56%)
M.Cap ( in Cr)44762.16
Divi's Lab (BSE)
peergroup  5404.00 (2.70%)
M.Cap ( in Cr)143414.09
Astrazeneca Pharma I (BSE)
peergroup  7996.95 (1.42%)
M.Cap ( in Cr)20213.75

Shareholding Pattern

PROMOTERS 74.56%
NON-INSTITUTION 22.4%
FII 1.9%
FI/BANKS/INSURANCE 0.01%
MUTUAL FUNDS/UTI 0%
GOVERNMENT 0%

About TTK Healthcare Ltd.

TTK Healthcare Ltd. was incorporated in the year 1958. Its today's share price is 1222. Its current market capitalisation stands at Rs 1735.2 Cr. In the latest quarter, company has reported Gross Sales of Rs. 7912.05 Cr and Total Income of Rs.8154.01 Cr. The company's management includes Subashree Anantkrishnan, Hastha Shivaramakrishnan, T T Mukund, S Kalyanaraman, V Ranganathan, N Ramesh Rajan, K Shankaran, R K Tulshan, T T Raghunathan.

It is listed on the BSE with a BSE Code of 507747 , NSE with an NSE Symbol of TTKHLTCARE and ISIN of INE910C01018. It's Registered office is at No 6 , Cathedral Road, , Chennai-600086, Tamil Nadu. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Aiyar & Co, PKF Sridhar & Santhanam LLP, S Viswanathan, S Viswanathan LLP

1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.
1.NSE exchange is Stopping the facility of Stop-Loss Market (SL-M) orders In option trade from 27th Sept 2021 to avoid freak trades and reduce its impact significantly. 2. Introduction of T+1 rolling settlement on optional basis. Stock Exchange may choose to offer T+1 settlement cycle. There shall be no netting between T+1 and T+2 settlements. Circular provisions come into force with effect from Jan: @SEBI_India 3. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 01, 2020. 4. Update your email id and mobile number with your stock broker / depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 5. Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month. 6.Do not share sensitive information like User ID, Password, OTP, etc., with anyone. Regards, Nirmal Bang.

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.
Close X
OPEN

DEMAT ACCOUNT

AND START YOUR

INVESTMENT

JOURNEY WITH US
(You will receive a Call & SMS from our end)
Popup-Character

Disclaimer: NIRMAL BANG SECURITIES PVT LTD: Investment in Securities market are subject to market risks. Read all the related documents carefully before investing. Please read the Do’s and Don’ts prescribed by the Commodity Exchange before trading. We do not offer PMS Service for the Commodity segment. Opening of account will not guarantee allotment of shares in IPO. Investors are requested to do their own due diligence before investing in any IPO. The securities quoted are exemplary and are not recommendatory. BSE (Member ID- 498): INB011072759, INF011072759, Exchange Registered Member in CDS; NSE MEMEBR ID- 09391): INB230939139, INF230939139, INE230939139; MSEI Member ID-1067): INB260939138, INF260939138, INE260939139: Single Registration No. INZ000202536, PMS Registration No: INP000002981; Research Analyst Registration No: INH000001766; NSDL/ CDSL: IN-DP-CDSL 37-99; Exchange Member ID: MCX - 56460, NCDEX - 1268, ICEX – 2073. Regd. Office: B-2, 301/302, 3rd Floor, Marathon Innova, Off Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013. Tel: 62738000/01; Fax: 62738010 | *NIRMAL BANG NIVESHALAYA PVT LTD: ARN – 111233, Mutual Fund Distributor. Mutual Fund Investments are subject to market risks. Please read the offer documents carefully before Investing.” Regd. Office: B - 201, Khandelwal House, Poddar Road, Near Poddar Park, Malad (East). Mumbai – 400097. | **NIRMAL BANG INSURANCE BROKING PVT LTD: IRDAI Registration No: 795 and Registration Code For the Insurance Broker: IRDAI/DB889/2021. Insurance is the subject matter of the solicitation. For more details on policy terms, conditions, exclusions, limitations, please refer/read policy brochure carefully before concluding sale.